摘要
目的本研究分析阿帕替尼联合长春瑞滨对晚期乳腺癌患者基质金属蛋白酶(MMPs)及PTEN/缺氧诱导因子1α(HIF1α)水平的影响。方法选取厦门市第五医院2017年1月至2018年12月收治的120例晚期乳腺癌患者作为研究对象。按照治疗方法分为对照组(n=60)和观察组(n=60),对照组接受阿帕替尼联合卡培他滨治疗,观察组接受阿帕替尼联合长春瑞滨治疗。比较两组临床疗效、治疗前后血清MMPs、PTEN及HIF1α水平的变化。结果观察组有效率及疾病控制率均明显高于对照组(P<0.05);两组治疗后血清MMP2、MMP9、TIMP1和TIMP2水平均明显降低(P<0.05),同时两组治疗后PTEN水平明显升高,HIF1α水平明显降低(P<0.05),且观察组上述指标变化较对照组更显著(P<0.05)。结论阿帕替尼联合长春瑞滨治疗晚期乳腺癌疗效良好,可有效改善患者MMPs、HIF1α以及PTEN蛋白水平。
Objective To analyze the effects of apatinib combined with vinorelbine on the levels of matrix metalloproteinases(MMPs)and phosphatase and tensin homolog deleted on chromosome ten(PTEN)/hypoxiainducible factor 1α(HIF1α)in patients with advanced breast cancer(ABC).Methods A total of 120 patients with ABC admitted to the Fifth Hospital of Xiamen from January 2017 to December 2018 were selected as study subjects.They were divided into the control group(n=60)and the observation group(n=60)according to the treatment method.The control group was treated with apatinib combined with capecitabine,and the observation group was treated with apatinib combined with vinorelbine.The clinical efficacy,changes of serum MMPs,PTEN and HIF1α levels before and after treatment were compared between the two groups.Results The response rate and dis ease control rate in the obs ervation group were s ignificantly higher than thos e in the control group(P<0.05).After treatment,the serum MMP2,MMP9,tissue inhibitor of metalloproteinase 1(TIMP1)and TIMP2 levels in both groups were significantly lower than those before treatment(P<0.05).Meanwhile,PTEN levels were significantly higher and HIF1α protein levels were significantly lower in both groups after treatment than those before treatment(P<0.05),and the changes of the above indexes in the observation group were more significant than those in the control group(P<0.05).Conclusion Apatinib combined with vinorelbine is effective in improving MMPs,HIF1α and PTEN protein levels in p atients with treating ABC.
作者
齐艳姝
傅鉴乾
黄如意
吴晗
QI Yanshu;FU Jianqian;HUANG Ruyi;WU Han(Department of Medical Oncology,the Fifth Hospital of Xiamen,Fujian,Xiamen 361101,China)
出处
《中国医药科学》
2022年第8期151-154,共4页
China Medicine And Pharmacy
